The Effect of Erigeron Injection on Acute Cerebral Infarction Serum VEGF, MMP-9 and EPC Levels

Phase 4

• Conditions: Cerebral Infarction
• Interventions: Drug: Erigeron Injection; Drug: placebo

• Registration Number: NCT01926834
• Lead Sponsor: Guangzhou University of Traditional Chinese Medicine

Brief Summary

To study the effects of Erigeron Injection on human serum VEGF, MMP-9 and EPC levels after acute cerebral infarction,test is made by random double-blind controlled.patients with acute cerebral infarction were divided randomly into erigeron injection+aspirin group,aspirin group,and health people. The main indexes are the serum level of VEGF, MMP-9 and EPC.The review is made by the reference to NIHSS and so on. So, Erigeron Injection have the function of promoting angiogenesis in multiple targets through this test.

Detailed Description

OBJECTIVE:

To study the effects of Erigeron Injection on human serum VEGF, MMP-9 and EPC levels after acute cerebral infarction.

METHOD:

40 patients with acute cerebral infarction(in accordance with the inclusion criteria) were divided randomly into erigeron injection+aspirin group,aspirin group,and 20 health people. Erigeron injection+aspirin group and aspirin group drew peripheral blood on the prior treatment,the posttreatment 1th, 3th and 7th day,and tested the level of VEGF, MMP-9 and EPC.Tested the health people one time.

Study Timeline

• Status Verified: 2013-08
• Study Start: 2013-08
• Primary Completion: 2013-08
• Study First Submitted: 2013-08-19
• Study First Submitted QC: 2013-08-19
• Last Update Submitted: 2013-08-19
• Study First Posted: 2013-08-21
• Last Update Posted: 2013-08-21
• Study Completion: 2014-03

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• patients aged no younger than 18yrs
• attack within 72 hours
• NIHSS score in the 2-25 points
• Ischemic Stroke occurred for the first time, or with a history of stroke disease but without sequelae
• Signed the informed consents

Exclusion Criteria

• patients aged younger than 18yrs
• Patients with tumor, coronary heart disease, valvular heart disease, psoriasis, rheumatism, hematologic diseases, infertility, varieties of acute inflammation
• Patients with severe cognitive impairment
• Refused to cooperate or been unable to cooperation for neurological disorders
• Cerebral hemorrhage or hemorrhagic cerebral infarction
• Unstable vital signs dued to massive cerebral infarction
• Patients with serious heart, liver and renal insufficiency

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Erigeron Injection	Erigeron Injection	Erigeron Injection, 30ml,qd,i.v., for 7 days
placebo	placebo	normal saline, 500ml,i.v.,qd, for 7 days

Primary Outcome Measures

Name	Time	Method
the serum level of VEGF,MMP-9 and EPC	0-7days

Secondary Outcome Measures

Name	Time	Method
National Institute of Health of stroke scale	0-7days